Abstract: The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.
Type:
Grant
Filed:
August 30, 2017
Date of Patent:
June 2, 2020
Assignee:
Societe des Produits Nestle SA
Inventors:
Yuanlong Pan, Brian Michael Zanghi, Jean-Christophe Bouthegourd
Abstract: A solid material adapted to kill bacteria in planktonic, spore and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The solid material includes a significant amount of one or more surfactants entrained in a crosslinked polymeric network.
Abstract: The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties; c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties; d) one or more, e.g. 1, 2 or 3, fillers, and e) one or more, e.g. 1, 2 or 3, disintegrants.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
May 12, 2020
Assignee:
Novartis AG
Inventors:
Hong Wen, Natrajan Kumaraperumal, Richard Nause
Abstract: A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.
Abstract: Disinfection foam having low levels of alcohol, comprising at least water, foaming agent, and polymeric type silver ion source, and a method of manufacturing the same. The present antimicrobial foams are especially suitable for hand sanitizer foams, shaving foams, dry cleansing foams for full body, leave on shampoos, face cleansing foams and multipurpose dry cleaning.
Abstract: The present disclosure relates generally to a composition comprising at least one capped oligomer, at least one solvent, at least one film former, and at least one monomer or polymer, said composition having a sward hardness <10 and >1 when applied to a glass plate.
Abstract: The present disclosure relates to agents for the oxidative coloring of keratinic fibers, which are characterized in hat they contain derivatives of anisole as novel developer molecules.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
April 14, 2020
Assignee:
Henkel AG & Co. KGaA
Inventors:
Antje Gebert-Schwarzwaelder, Ralph Nemitz, Astrid Kroos, Annika Koenen
Abstract: Compositions for appetite control and/or regulation or loss of weight are described. The described compositions comprise a unique combination of ingredients, the combination including at least botanical substances, amino acids, and one or more metals, and may comprise and in some embodiments do further comprise one or more vitamins and/or caffeine. The compositions are taken by mouth and provide a multi-targeted approach for the regulation and control of appetite for subjects taking the composition. The composition is preferably taken before a meal. A recommended dose includes at least one dose of the described composition per day.
Abstract: A solid material adapted to kill bacteria in planktonic, spore and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The solid material includes a significant amount of one or more surfactants entrained in a crosslinked polymeric network.
Abstract: The present invention relates to skin dressings that are useful in the treatment of conditions associated with tissue ischaemia and skin lesions including those that are infected, such as burns and surgical wounds and chronic wounds such as but not limited5 to diabetic foot ulcers and venous leg ulcers. The skin dressings are also useful to effect transdermal delivery of pharmaceutically active agents.
Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is compound represented by the following formula (I) in combination with (i) one or two or more components selected from the group consisting of D-mannitol, lactose, corn starch, and crystalline cellulose, (ii) carmellose calcium, and (iii) colorants.
Abstract: The present disclosure relates to a film for oral hemostasis and wound protection and, more particularly, to a film for oral hemostasis and wound protection which, being attached to a wound area in an oral cavity, delays or prevents microbleeds and controls medicinal component release. The film provided by the present disclosure is capable of including a polyol, an alcohol and a biodegradable polymer in the state of partial swelling, thereby locally absorbing blood or pus or arresting hemorrhage. Moreover, due to its high elongation ratio, the film provided by the present disclosure is capable of maintaining its adhesive force even when having blood, saliva and pus absorbed inside an oral cavity and conveniently deforming according to the shape of a seriously corrugated local area, which causes only slight foreign body sensation even after a long period of time of attachment on to the local area.
Abstract: Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an antithrombotic agent for the treatment of stroke, acute coronary syndrome, pulmonary embolism, atrial fibrillation, venous and arterial thromboembolism, disseminated intravascular coagulation (DIC), deepvein thrombosis (DVT), peripheral artery disease, trauma-induced coagulopathy, extracorporeal circulation, cancer-associated thrombosis, sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), or inflammation.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
March 10, 2020
Assignees:
The University of British Columbia, The Board of Trustees of the University of Illinois
Inventors:
Jayachandran Kizhakkedathu, James H. Morrissey, Richard J. Travers, Rajesh Shenoi, Manu Thomas Kalathottukaren
Abstract: A composition for injection into a host is provided according to the embodiments of the present application. The composition consists of microparticles consisting essentially of an opioid antagonist and a polymeric binder selected from the group consisting of poly(glycolic acid), poly-d,l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and polyphosphazines; an injection vehicle, wherein said injection vehicle consists of water, a viscosity enhancing agent, a wetting agent, and a tonicity adjusting agent; and a steroidal anti-inflammatory agent.
Abstract: A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.
Abstract: A microcapsule encapsulates a payload agent, the microcapsule having a microcapsule shell material that is rupturable (e.g., to release the encapsulated payload agent) via a retro-dimerization reaction.
Type:
Grant
Filed:
November 8, 2017
Date of Patent:
February 4, 2020
Assignee:
International Business Machines Corporation
Inventors:
Scott B. King, Brandon M. Kobilka, Joseph Kuczynski, Jason T. Wertz
Abstract: The present invention relates to water treatment. In one embodiment there is provided a method of treating an aqueous system to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method comprises adding treatment agents to said aqueous system and wherein said treatment agents comprise: (a) a phosphonium compound; and (b) a halogen oxide compound.
Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
January 7, 2020
Assignee:
INSMED INCORPORATED
Inventors:
Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
January 7, 2020
Assignee:
ARCTURUS THERAPEUTICS, INC.
Inventors:
Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis